Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Gains from Sales and Divestitures: 2024

Historic Gains from Sales and Divestitures for CorMedix (CRMD) over the last 1 years, with Dec 2024 value amounting to $62,241.

  • CorMedix's Gains from Sales and Divestitures was N/A to $62,241 in Q4 2024 from the same period last year, while for Dec 2024 it was $62,241, marking a year-over-year change of. This contributed to the annual value of $62,241 for FY2024, which is N/A change from last year.
  • Per CorMedix's latest filing, its Gains from Sales and Divestitures stood at $62,241 for Q4 2024, which was up 45.27% from $42,844 recorded in Q3 2024.
  • CorMedix's Gains from Sales and Divestitures' 5-year high stood at $62,241 during Q4 2024, with a 5-year trough of $42,844 in Q2 2024.
  • Its 1-year average for Gains from Sales and Divestitures is $49,310, with a median of $42,844 in 2024.